Altimmune, Inc. Common Stock
ALTAltimmune, Inc. is a biotechnology company focused on developing immunotherapeutic solutions and vaccines for infectious diseases, cancer, and metabolic disorders. The company leverages innovative technology platforms to create treatments aiming to enhance immune responses and improve patient outcomes.
Company News
The global biodefense market is projected to grow from USD 16.81 billion in 2024 to USD 32.87 billion by 2034, driven by advancements in biotechnology, increased government funding, and growing awareness of biological threats.
The Schall Law Firm is pursuing a class action lawsuit against Altimmune for allegedly making false and misleading statements about its drug candidate Pemvidutide, which failed to achieve statistically significant results in its Phase 2B MASH trial.
Pfizer's experimental obesity drug danuglipron failed due to safety concerns, leading the company to consider acquiring Altimmune or Viking Therapeutics, which have promising obesity drug candidates. Pfizer may wait to see how its other obesity drug, PF-07976016, performs in clinical trials before making an acquisition decision.
Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen are included in this Analyst Blog.
The obesity drugs that powered huge investor gains in 2023 are poised to inspire more corporate dealmaking, scientific breakthroughs and better patient access in the year ahead, analysts say.
